This clinical trial is focused on studying a type of lung cancer known as anaplastic lymphoma kinase positive non-small cell lung cancer (ALK+ NSCLC). This is a specific form of lung cancer where the cancer cells have a change in the ALK gene, which can affect how the cancer grows. The study is testing a medication called brigatinib, which is taken as a film-coated tablet. Brigatinib is being compared to other similar medications, known as second-generation tyrosine kinase inhibitors (TKIs), which include ceritinib and alectinib. These medications are designed to target and block the activity of the ALK protein, which may help to slow down or stop the growth of cancer cells.

The purpose of this study is to compare how effective brigatinib is when used as the first treatment option for patients with ALK+ NSCLC, compared to other second-generation TKIs. Participants in the study will receive either brigatinib or another TKI, and their progress will be monitored over time. The study will look at how long the treatment can prevent the cancer from getting worse, as well as other factors like overall survival and the impact on the brain, which is a common area for cancer to spread in ALK+ NSCLC.

Participants will take the medication orally, and the study will last for a period of up to 68 weeks. Throughout the study, researchers will collect information to understand how well the treatments work and how they affect the participants’ quality of life. The study will also explore different genetic changes in the cancer cells, such as TP53 mutations, to see if these affect how well the treatments work. This research aims to provide valuable insights into the best treatment options for patients with ALK+ NSCLC.